alexa
Reach Us +44-1904-929220
DNA Methylome Analysis In Blood Using The MethDet Technology: A Universal Media For Clinical Biomarkers | 8933
ISSN-2155-9929

Journal of Molecular Biomarkers & Diagnosis
Open Access

Like us on:

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

DNA methylome analysis in blood using the MethDet technology: A universal media for clinical biomarkers

4th International Conference on Biomarkers & Clinical Research

Victor V. Levenson and Anotoliy A Melnikov

AcceptedAbstracts: J Mol Biomark Diagn

DOI: 10.4172/2155-9929.S1.019

Abstract
E arly detection and differential diagnosis of a disease is a significant challenge. Asymptomatic disease present in an unknown location in the body has to be identified precisely, inexpensively, and quickly. Only a few types of biomarkers can accomplish this task, including epigenetic biomarkers based on Methylation of cell-free circulating DNA in blood. In this presentation an overview of a novel technology for genome-wide detection of DNA methylation in ultra-small samples, MethDet, will be presented alongside with results of the proof-of-principle platform for identification of abnormal DNA methylation patterns in each sample. This platform allows identification of advanced adenoma of the colon, ductal carcinoma in situ , and stage I/II colon cancer. The possibility of differential diagnosis by blood analysis has been established by comparison of patterns between benign lesions of the breast vs. ductal carcinoma, and benign ovarian disease vs. adenocarcinoma of the ovary. Application of DNA methylome-wide analysis to differential diagnosis of cancer, psychiatric, and neurological diseases will be discussed. Drug-specific changes in DNA methylation patterns detected in cell-free circulating DNA from blood of drug-exposed patients will be demonstrated
Biography
Victor V. Levenson received his M.D. from the 2 nd Moscow State Medical Institute in Moscow, USSR and his Ph.D. in Cellular and Molecular Biology from the Institute of Molecular Biology in Moscow, USSR, where he worked as a Junior Scientist, then Scientist, and Group Leader. After coming to the US he was on faculty at Univercity of Illinois at Chicago, Nothwestern University and Rush University Medical Center where he developed the proprietary MethDet technology. In 2010 he has co-founded US Biomarkers, Inc where he serves as President and CEO. He left academia in 2012 to concentrate on commercialization of biomarkers developed by the MethDet approach
Relevant Topics
Top